Objective To examine whether blocking multiple points of the angiogenesis pathway by
addition of sorafenib, a multi-kinase inhibitor against VEGFR2/3, Raf, c-Kit, and PDGFR, to …

Background Bavituximab, an immunomodulator, targets phosphatidylserine (PS), a
membrane lipid externalized on tumor and endothelial cells in response to sorafenib …

A number of molecularly targeted anticancer drugs that efficiently inhibit receptor tyrosine
kinases, socalled receptor tyrosine kinase inhibitors (TKIs), have been developed. Although …

Requirements of large numbers of transferred T cells and various immunosuppressive
factors and cells in the tumor microenvironment limit the applications of adoptive T cells …

Purpose Inhibition of the vascular endothelial growth factor receptor (VEGFR) with tyrosine
kinase inhibitors (TKIs) is associated with cutaneous adverse effects that increase patient …

Angiogenesis has been described as one of the hallmarks of cancer, playing an essential
role in tumor growth, invasion, and metastasis. Antiangiogenic therapy was initially …

Targeted treatments have distinctive side effects: dermatologic problems (rash, hand-food
skin reaction, skin/hair whitening), endocrine dysfunction (hyperglycemia, hypothyroidism …

Purpose: The recurrent/progressive glioblastoma multiforme (GBM) carries a dismal
prognosis and the definitive treatment strategy has not yet been established. This study …

Background Sorafenib included in Chinese medical insurance is the earliest targeted drug
for radioactive iodine refractory differentiated thyroid cancer (RR-DTC). This study is to …

Background The purpose of this study was to investigate the usefulness of a hydrocolloid
dressing containing ceramide for hand-foot skin reaction (HFSR) on the soles of the feet in …